Celiac disease (CD) was originally considered a pediatric disorder characterized by malabsorption and steathorrhea. Subsequently it was recognized that CD could affect adults at any age. Currently, in some centers, the greatest number of diagnosis of CD is performed in adults between 30 and 50 years. An overall decrease in the prevalence of diarrheal presentations over the past 2 decades, accompanied by an increase in "non-classical" manifestations of the disease, has been well described in both children and adults. Among children, clinical presentation is affected especially by the age. Very young children (< 3 years old) present more often with diarrhea, abdominal distension, and failure to thrive, whereas older children and adolescents are more likely to present with other gastrointestinal symptoms (recurrent abdominal pain, vomiting, or constipation) or extraintestinal symptoms. In adults, the major mode of presentation is diarrhea, although this presentation occurs in fewer than 50% of patients, and non-specific gastrointestinal symptoms, which bear a large degree of overlap with functional dyspepsia, irritable bowel syndrome or functional diarrhea.
Introduction
Celiac disease (CD) is an immune-mediated systemic disorder elicited by gluten and related prolamines in genetically susceptible individuals and characterized by the presence of a variable combination of gluten-dependent clinical manifestations, CD-specific antibodies, HLA-DQ2 or -DQ8 haplotypes, and enteropathy 1 . In genetically predisposed individuals, CD is precipitated by the ingestion of gluten, which are storage proteins in wheat (gliadin), rye (secalin) and barley (hordein). CD is a chronic, multi-organ disease in which small intestinal mucosal damage may lead to malabsorption of nutrients. The treatment of CD, adherence to a gluten free diet, was discovered by the Dutch pediatrician Willem-Karel Dicke (1905 Dicke ( -1962 2 .
Genetic, immunology and environmental factors are important in the development of CD. The disease has a strong genetic component and the principal determinants are the class II HLA-DQ2 and -DQ8 genes 3 . CD is primarily a T cell-mediated immune disorder and in the small intestinal mucosa of individuals with CD, CD4+ T cells recognize gluten peptides selectively in the context of HLA-DQ2 or -DQ8 molecules 4 . The enzyme transglutaminase 2 (TG2) deaminates the positive charged gluten peptides, enhancing their binding to HLA-DQ2 and -DQ8 molecules. Both gluten-specific CD4+ T cells and cytotoxic intraepithelial T lymphocytes (IELs) play a key role in the development of CD, as defined by the presence of anti-TG2 antibodies and villous atrophy. The most important environmental factor related to CD is gluten, but other factors, such as infections, dysbiosis and drug exposure have been implicated 5, 6 . CD is a common but frequently unrecognized disease, in part because of its variable clinical presentation and symptoms 7 . Screening studies have shown that CD is severely underdiagnosed, with of about 1%-3% among the European population, both in adults as in children [8] [9] [10] [11] . Because CD can be very effectively treated with a gluten-free diet (GFD) it is important to identify people with the undiagnosed disease so as to provide satisfactory individual treatment. To improve the recognition of CD and to increase the 295 
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number of people diagnosed with the condition, a significant number of diagnosis clinical guidelines has been published over the last years 1, [12] [13] [14] [15] . Besides, the Oslo and London Consensuses recommendations tried to reached agreement on the definition of terms related to CD and/or gluten sensitivity to improve communication among researchers, clinicians and the general public (Table 1) 16, 17 . 17 and to ESPGHAN guideline 1 
.
Presence of CD-specific antibodies and compatible HLA but without histological abnormalities in duodenal biopsies. The patient may or may not have symptoms and signs and may or may not develop a gluten-dependent enteropathy later.
Not used
Latent CD Presence of compatible HLA but without enteropathy in a patient who has had a gluten-dependent enteropathy at some point in his or her life. The patient may or may not have symptoms and may or may not have CDspecific antibodies.
Refractory CD Persistent or recurrent malabsorptive symptoms and signs with villous atrophy despite a strict GFD for more than 12 months
CD autoimmunity
Relates to increased anti-TG2 or EMA on at least two occasions when status of the biopsy is not known. If the biopsy is positive, then this is CD, if the biopsy is negative than this is potential CD
Genetically at risk of CD
Family members of patients with CD that test positive for HLA-DQ2/DQ8
Non-celiac gluten sensitivity
Relates to one or more of a variety of immunological, morphological or symptomatic manifestations that are precipitated by the ingestion of gluten in people in whom CD has been excluded
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OSLO Consensus ESPGHAN guideline
Gluten ataxia
Idiopathic sporadic ataxia and positive serum antigliadin antibodies even in the absence of duodenal enteropathy
Dermatitis herpetiformis
Cutaneous manifestation of small intestinal immune-mediated enteropathy precipitated by exposure to dietary gluten. It is characterized by herpetiform clusters of pruritic urticated papules and vesicles on the skin, especially on the elbows, buttocks and knees, and IgA deposits in the dermal papillae. DH responds to a GFD
Terms to avoid
Typical CD; Atypical CD; Silent CD; Overt CD; Latent CD Typical CD; Atypical CD; Classical CD; non-classical CD
Clinical Manifestations
CD was originally considered a pediatric disorder characterized by malabsorption and steathorrhea. Subsequently it was recognized that CD could affect adults at any age. Currently, in some centers, the greatest number of diagnoses of CD is performed in adults between 30 and 50 years 18 . Most children and adults with CD diagnosed before 1980 presented with diarrhea.
With the advent of serologic tests in the 1980s, the wide spectrum of clinical manifestations became apparent. An overall decrease in the prevalence of diarrheal presentations over the past 2 decades, accompanied by an increase in "non-classical" manifestations of the disease, has been well described in both children and adults 7, 19, 20 . (pretesting group) to 44% (testing group). In the testing group, classic CD remained predominant (67%) in young children (<3 years), whereas atypical gastrointestinal and silent presentations predominated in older children. The primary symptoms, signs or associated conditions that led to intestinal biopsy are presented in Table 3 . In the last years, several studies have suggested a protective role of breast feeding and/or the timing and quantity of gluten introduction in the subsequent development of CD in children 24 . Especially, the data from the Swedish epidemic of symptomatic CD during the mid-1980s suggested that prolonged breast feeding during the introduction of gluten-containing feeding was associated with a reduced risk of developing CD in infancy 25 . However, recently two multicenter, randomized, double-blind, placebo-controlled dietary-intervention studies have reported that neither the delayed introduction of gluten nor breast-feeding modified the risk of celiac disease among at-risk infants 26, 27 .
Adults
In adults, the mean age of CD presentation is 44 years (range 1-81 years), with a clear female predominance (1: 3) , that has also been shown in young children 26 . Approximately 15-25% of cases are diagnosed at an age equal to or greater than 65 years 18 . In some cases, a history of growth failure or other symptoms suggestive of unrecognized childhood CD is discovered. The classic presentation of the disease with malabsorption, diarrhea, weight loss and abdominal distension is less common than in children 19 . The major mode of presentation is diarrhea, although this presentation occurs in fewer than 50%
of patients, and non-specific gastrointestinal symptoms, which bear a large 28, 29 .
Dyspepsia is a common symptom in CD patients, which may be present in 40-60% of the cases at the time of diagnosis 30, 31 . conditions, can be a common mode of presentation of CD in adults (Table   2) 13,39
.
Finally, serologic screening of high-risk groups, especially relatives of patients with CD, has increased detection of the disease both in children as in adults, some of whom are asymptomatic or present with mild and unspecific symptoms 21 .
Diagnostic Criteria
Children
Strict criteria for CD diagnosis in children were first established by the European Society of Pediatric Gastroenterology and Nutrition (ESPGAN) in 1969 40 . The so-called 3 biopsies rule recommended performing at least three small bowel biopsies (SBB): the first one at clinical suspicion and while the child was on a gluten containing diet, the second after a period of gluten-free diet, and the third after gluten reintroduction, i.e. after performing a gluten challenge (GC). Characteristic histological lesions in the first SBB lead to CD suspicion, but a definite diagnosis of CD was finally confirmed only after in the 3rd biopsy histological relapse related to GC was verified. This strict diagnostic protocol aimed at demonstrating that gluten sensitivity was a permanent condition and to avoid misdiagnosis of transient gluten intolerance associated to other conditions especially in young infants 40 .
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After 20 years experience in large series of children it was shown that GC could probably be avoided in 95% of the cases 41 ; accordingly diagnostic criteria were modified in 1990 and GC was restricted to infants younger than 2 years at the first biopsy to exclude other causes of enteropathy or whenever the initial diagnosis is uncertain; this latter covers different special circumstances such as gluten exclusion prior to or without a biopsy or uncharacteristic histological lesions for CD at diagnosis 42 . Moreover, the new criteria had for the first time a disease marker to rely on, i.e. the antigliadin antibodies (AGA), who had recently been found to be associated to active CD [43] [44] [45] ; so it was considered that the presence of AGA in serum at disease onset, followed by antibody vanishing after gluten withdrawal, added support to the diagnosis 42 . However, further development of antiendomysial antibodies (EMA) in the late 80's [45] [46] [47] [48] , followed by TG2 being recognized as the autoantigen of CD in the 90´s, represented a true revolution in the field of CD diagnosis 49 . It was indeed shown that both EMA and anti-TG2 recognize the same autoantigen and overall display a sensitivity and specificity for CD diagnosis higher than 95% [49] [50] [51] . A new serological tests for antibodies against deaminated gliadin peptides (DGP) 52 has more recently turned out to display a higher sensitivity and specificity than conventional AGA, thus replacing the later ones for diagnostic purposes.
Although pediatric series are shorter as compared to adults´ ones, correlation between duodenal histopathology and anti-TG2 levels in pediatric patients with CD has been reported, higher levels being associated with villous atrophy [53] [54] [55] . Thus, it has recently been suggested that strongly positive anti-TG2 antibodies levels might be considered sufficient for CD diagnosis in children and replace the SBB in the diagnostic work up 53 .
Moreover the strong association of CD with genetic markers HLA-DQ2 and -DQ8, which combined reach a sensitivity of 96%, implies a negative result of HLA-DQ2 and/or -DQ8 renders CD diagnosis unlikely [56] [57] [58] .
Additionally, a very high relapse rate after GC in children younger than 2 years with positive EMA and villous atrophy at diagnosis has been demonstrated, supporting the view that routine GC should not be mandatory in these cases 59 .
Not surprising a recent survey conducted among ESPGHAN members revealed that about 90 % of responders requested a revision and modification of the 1990 diagnostic criteria; 44% wanted to omit the first SBB in specific circumstances, the majority of them declaring that no first biopsy should be . In summary, the new guidelines state that SBB may not be mandatory for CD diagnosis in HLA-DQ2 and/or -DQ8 symptomatic patients with anti-TG2 over 10 times the upper limit of normal (ULN) and positive EMA. As for GC they establish that GC is no longer obligatory in all cases that underwent SBB before the age of 2, but only in unclear cases. These guidelines have been validated by a recently published retrospective study 62 and a prospective international multicenter one (PROCEDE, www.procede2011.jimdo.com) is currently on-going.
Who to Test for CD?
According to the new 2012 ESPGHAN guidelines for CD diagnosis in children and adolescents, beside patients with the classic clinical picture, i.e. malabsorption syndrome with chronic diarrhea, weight loss, abdominal distension and anorexia, children with a wide spectrum of other
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gastrointestinal and extraintestinal symptoms -most of them also reported in adults -should be tested for CD; these are shown in Table 4 . Failure to thrive, short stature and pubertal delay are CD features specific for the pediatric age range and should thus prompt serological testing as well. Also asymptomatic individuals pertaining to the so called high risk groups and specially those with a first degree relative with confirmed CD should be screened for CD (Table 4) 1 . Immunofluorescent tests such as EMA are subjected to interobserver variability. Despite these limitations, the specificity of EMA is 98% to 100%
in expert laboratories 51, 63 and is thus considered the reference standard for CD-specific antibody.
The performance of a particular antibody test depends on patient characteristics (age, genetic predisposition, IgA deficiency), on pretest probability, on the used commercial kit and last but not least the expertise of the laboratory is also relevant 51 .
However in children serological tests display a much higher efficiency as compared to adults , partially because usually more severe histological lesion are found in the pediatric age range. So in the 2012 ESPGHAN guidelines it is stated that in absence of CD specific antibodies (anti-TG2 and EMA) the diagnosis of CD is unlikely 1 .
According to the ESPGHAN evidence report on CD serology 61 , EMA display the best positive and negative likelihood ratios, followed by anti-TG2.
Furthermore, EMA results were more homogeneous than results obtained with other CD antibody tests and had a high diagnostic odds ratio (OR = 553.6).
Thus CD is likely if the EMA test is positive. Moreover EMA positivity also is associated with the later development of villous atrophy in the few reported cases who initially had normal small-intestinal architecture 64, 65 .
High concentrations of anti-TG2 in serum predict villous atrophy better than low or borderline values 54, 55, 66 and these studies suggest that high anti-TG2 antibody levels can be defined as those exceeding 10 times the upper limit of normal (ULN) depending on the cut off of each test (concentration-dependent antibody tests based on calibration curves) 55, 66, 67 .
Anti-DGP antibodies performed favorably and much better than antibodies against native gliadin, however their performance is inferior compared with
anti-TG2 or EMA assays 55, 61 ; In addition, their role in the diagnosis of children younger than 2 to 3 years requires further assessment.
Anti-TG2 antibody detection also can be done from the blood at the point of contact using rapid test kits (POC test) 68, 69 , but although they may achieve a high accuracy for CD diagnosis (pooled sensitivity of 96.4%, pooled specificity of 97.7%) 61 , performance of these tests needs to be confirmed not only in high prevalence populations as current published studies, but also in less selected populations and/or when handled by laypeople or untrained medical staff. Also anti -DGP based POC have lately been made available, although only very few studies have been reported up to now, effectiveness seems to be similar to the previous ones (personal observation).
Diagnostic Confirmation
In the last few years the leading role of histology for the diagnosis of CD has been questioned 53, 55, 63, 65 . One of the mean reasons is that histological findings are not specific for CD, especially low grade lesions; these can be found in other entities, such as cow's milk or soy protein hypersensitivity, intractable diarrhea of infancy, infestation with Giardia lamblia, immunodeficiencies, tropical sprue, and bacterial overgrowth (Table 5 ).
Another issue is that lesions may be patchy 70 , they can occur in the duodenal bulb only 71 , but the most important matter of concern is that interpretation depends on preparation of the mucosa sample and above all that a high interobserver variability has been acknowledged or low levels may be found in non-CD conditions, specially autoimmune diseases and are not related to histological lesion 55, 67, 73 . . The description of the lesions according to Marsh -Obberhuber classification are described in Table 6 75,76
. or the presence of IgA anti-TG2 deposits in the mucosa 78, 79 .
These deposits in the mucosa seem to be specific for CD and to predict the 
Role of HLA-DQ2/DQ8 Genotyping in Celiac Disease
HLA-DQ2 and -DQ8 testing is valuable because CD is unlikely if both haplotypes are negative 1, 57, 58 . Thus its main utility is to discard patients at risk for CD and accordingly HLA testing is useful to select asymptomatic persons with CD-associated conditions or pertaining to high risk groups for further CD-specific antibody testing 1 . In clinical practice it is noteworthy to stress the relevance of HLA typing of siblings or the offspring of CD patients as it will establish those at risk in which periodic testing for CD markers may be recommended, especially during the pediatric age range.
Moreover HLA testing should be performed when the diagnosis of CD is unclear, for example, in patients with negative CD-specific antibodies and mild histological lesion. In children with a strong clinical suspicion of CD and high specific CD antibodies, if no SBB is going to be performed HLA-DQ2/DQ8 typing is strongly recommended to add strength to the diagnosis 1 .
Special Situations
In subjects with humoral IgA deficiency, corresponding IgG class CD-specific antibodies should be measured, preferably IgG anti-TG2, but alternatively EMA-IgG, IgG anti-DGP or blended kits for both IgA and IgG antibodies 1, 48 . Thus it is important to exclude IgA deficiency by measuring serum total IgA levels moreover considering IgA deficiency is more prevalent in CD as compared to the general population.
Children, mainly infants, presenting with a severe malabsorption syndrome and malnutrition, may exceptionally been started on a GFD while awaiting the results of HLA and EMA testing 1 . If the findings do not allow a definite diagnosis and due to a poor clinical condition the SBB has to be postpone, additional workup such as looking for IgA anti-TG2 deposits in the mucosa may be helpful. Due to persistence of anti-TG2 deposits for months after a GFD has been initiated, the presence of deposits can be used as a high specific test for CD whenever the patient has started dietary restrictions before a definite diagnosis has been achieved 79, 80 . Patients with associated autoimmune conditions may display false positive anti-TG2 or fluctuating results, usually at low levels 65, 73 ; however in type 1 diabetes, especially at the initial stages of the disease, higher levels of EMA and anti-TG2 can be detected, decreasing to below ULN on follow up.
Celiac Disease Diagnostic Approach in Clinical Practice
The new 2012 ESPGHAN guidelines include 2 practical algorithms for CD diagnosis, one to be applied to symptomatic cases ( Figure 1 ) and another for asymptomatic individuals pertaining to high-risk groups (Figure 2 . It should be stressed that initial evaluation has to be performed while the child is on a gluten containing diet, thus before dietary restrictions are recommended.
In children and adolescents with otherwise unexplained signs and symptoms suggestive of CD it is recommended to start the diagnostic approach by IgA anti-TG2, together with total serum IgA to rule out IgA deficiency; in this situation IgG anti-TG2 testing is recommended (Figure 1 ). Truly there is no evidence on how frequently the testing should be performed.
If high anti-TG2 are found, as persons belonging to this population more often have false-positive anti-TG2 results, they should always be diagnosed after performing a SBB so as to have histological proof of CD diagnosis and thus support the need for a lifelong adherence to a strict gluten free diet 73 . If anti-TG2 levels are positive but low, that is <3 times ULN, a false-positive result has to be considered. In the absence of any signs or symptoms, follow up while still on a normal gluten-containing diet with repeated serological testing should be advised; in these cases, anti-EMA testing may be helpful to distinguish between false-and true-positive anti-TG2. If EMA is positive, the likelihood for CD increases and the patient should be referred for SBB. If EMA is negative, follow up and repeated testing is advisable.
A simple scoring system (Table 7) was also proposed by the working group which aimed at simplifying the diagnosis in obvious cases, thus enabling CD recognition at initial assessment, even in cases with no initial SBB and to avoid overdiagnosis in patients presenting only with non specific findings 1 .
However prospectively validation in a large series of cases is required before it can be routinely recommended in clinical practice.
Another score system proposed by Catassi et al. (Table 8 ) is further discussed in section 3.2.9.; as compared to the previous one, histology evaluation is required in all cases 82 .
Adults
Despite evidence of increasing rates of diagnosis, CD continues being an infradiagnosed disease in adults. It has been estimated that at least 75% of the cases remain undiagnosed 83 . Furthermore, there is often a delay in the diagnosis of the disease with a mean of 5 to 11 years from the onset of symptoms to diagnosis 18, 84 . These data may be explained by several facts:
1. The classic presentation of the disease is uncommon in adults. The major mode of presentation is diarrhea and nonspecific gastrointestinal symptoms which bear a large degree of overlap with functional dyspepsia, irritable bowel syndrome (IBS) or functional diarrhea 28 . 
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Points
Symptoms
Malabsorption syndrome
Other CD-relevant symptom OR having T1DM OR being a 1 st-degree family member Asymptomatic Comments and Explanations for Use. *Biopsy items were graded by taking into account Villanacci scoring and the clinical utility of the results. We assumed that Marsh 0 or 1 results without any further information could be nonspecific. In contrast, demonstration of antibodies bound to tissue TG2 in the small bowel adds information to the diagnosis (when available). It is possible to diagnose CD as before even without this possibility. It is not necessary to have an EMA testing facility, but it is a clear advantage. *Some findings that make CD improbable are resulting in negative scoring points. *The sum of 4 points may be collected from findings registered at different time points during follow-up if they can be assumed to be gluten dependent. For example, an infant having villous atrophy before the introduction of gluten and normal biopsy at the age of 6 years while normally eating gluten will receive 0 for biopsy. Notes: A family history of celiac disease adds evidence to the diagnosis; in symptom-free patients, particularly young children, it is advisable to confirm antibody positivity on 2 or more blood samples taken at least 3 months apart; in selected cases a gluten challenge after at least 2 years of gluten-free diet might be required for diagnosis confirmation. 1 Examples of typical symptoms are chronic diarrhea, growth delay (children) or weight loss (adults) or iron deficiency anemia. 2. Some antecedents, such as growth failure in childhood, iron-deficiency anemia, premature reduced bone mineral density, recurrent oral apthous, dermatological lesions or infertility may be often overlooked.
Gastroenterologist's questions have focused exclusively on gastrointestinal symptoms, forgetting that CD is a disorder with a multisystemic expression.
3. Currently, active case-finding (serologic testing for CD in patients with symptoms or conditions closely associated with CD) is the favored strategy to increase detection of CD. However many adults with CD has mild forms of enteropathy (Marsh 1, 2 and 3a) in which a positive result of CD-specific serology may be lower than 30% 85, 86 .
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Consequently, active case-finding may increase detection of CD among patients with symptoms although this strategy might be insufficient to detect all adults with CD 10 .
With the objective of improve the recognition and diagnosis of CD several guides to clinical practice have been published [12] [13] [14] [15] . In general, these guidelines recommend offering serologic testing for CD in patients with symptoms or conditions closely associated with CD ( Table 2 ). The confirmation of a diagnosis of CD should be based on a combination of findings from the clinical scenario, CD-specific antibodies, upper endoscopy with duodenal biopsies, HLA-DQ2/DQ8 genotyping, and the response to a GFD. A summary of the specific recommendations from these guidelines to improve the diagnosis of CD is showed below.
When to Test for Celiac Disease?
There is no consensus regarding which symptoms, laboratory abnormalities, and/or associated diseases require evaluation for CD. The frequency of CD in common clinical scenarios varies from modestly elevated, such as irritable bowel syndrome, to substantially elevated, such as unexplained iron-deficiency anemia. Clinical guidelines 13, 14 recommends to offer serological testing in patients with conditions in which CD occurs more frequently than in the general population and/or for whom a GFD may be beneficial (Table 2 ). As in children, serologic testing of CD-specific antibodies is the preferred initial approach to find CD in adults, and TG2-based assays (EMA and anti-TG2) the most accurate tests. The sensitivity and specificity of the IgA anti-TG2 for untreated CD is about 95%, but its sensitivity is lower in case of mild histological lesions (no villous atrophy) 85, 86 . The higher the titer of the test, the greater the likelihood of a true positive result. There are recognized differences in test performance between the various commercially available test kits, but overall there is consistency in the sensitivity and specificity of the test 87 . Antibodies directed against native gliadin are not recommended for the primary detection of CD 14 .
IgA deficiency is more common in CD than in the general population. In patients in whom there is a high pre-test prevalence of CD, the measurement of IgA levels should be considered, especially if IgA-based celiac serology test is negative. One approach is to measure total IgA at the beginning of testing to determine whether IgA levels are sufficient and, if not, to incorporate
IgG-based testing into the serology testing cascade (DGP-IgG and/or IgG anti-TG2) 14 .
The antibodies directed against deaminated gliadin products as well as the self-antigen TG2 are dependent on the ingestion of gluten. The reduction or cessation of dietary gluten leads to a decrease in the levels of all these celiac-associated antibodies to normal concentrations. Therefore, all diagnostic Combining several tests for CD in lieu of IgA anti-TG2 alone may marginally increase the sensitivity for CD but reduces specificity and therefore are not recommend in low-risk populations 14 .
If the suspicion of CD is high, intestinal biopsy should be pursued even when serologies are negative (Figure 3) . 
Confirmatory Testing in Celiac Disease
The confirmation of a diagnosis of CD should be based on a combination of findings from the medical history, physical examination, serology, and upper endoscopy with histological analysis of multiple biopsies of the duodenum 14 .
Upper endoscopy with small bowel biopsy is a critical component of the diagnostic evaluation for persons with suspected CD and is recommend to confirm the diagnosis. Histological changes associated with the disease can be classified according to Marsh, Marsh modified (Oberhuber) , or the more recent, simplified Corazza classification (Table 6) 
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. A positive CD-specific serology in patients with villous atrophy confirms the diagnosis of CD.
However, a negative CD-specific serology in patients with enteropathy does not completely exclude the diagnosis of CD though it does make it much less likely. Histological response to GFD and HLA genotyping may help to rule out or confirm the diagnosis of CD in patients with sero-negative CD 14 .
Histological abnormalities associated with CD can be patchy, therefore multiple biopsies of the duodenum (one or two biopsies of the bulb and at least four biopsies of the distal duodenum) are recommended to confirm the diagnosis of CD 89, 90 . Lymphocytic infiltration of the intestinal epithelium in the absence of villous atrophy is not specific for CD and other causes should be considered (Table 5) 91, 92 . The diagnosis may be confirmed when there is concordance between the serologic results and the histological findings and the symptoms resolve subsequently on a GFD. However, there are other situations in which it is possible to establish a diagnosis of CD although the result of CD-specific serology is negative 82 .
Role of HLA-DQ2/DQ8 Genotyping in Celiac Disease
HLA-DQ2/DQ8 heterodimers are present in almost all patients with CD.
Testing negative for both HLA-DQ genotypes makes CD diagnosis very unlikely. Among patients not carrying these heterodimers, the majority encoded half of the HLA-DQ2 heterodimer. Because HLA-DQ2 is present in 
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. The utility of HLA testing in other at-risk groups (such as type I diabetics or family members) is more limited because a high proportion of these subjects carry the CD susceptibility alleles.
Patients With Enteropathy But Negative CD-Specific Serology
This is a matter of crucial importance, especially in the adult population.
In fact, the true prevalence of CD in this population has been underestimated, because both in population screening programs, as in symptomatic or high genetic risk people, intestinal biopsy is indicated only for positive serology. However, there is evidence that serology sensitivity is lower among adults with mild histological lesions (no villous atrophy;
Marsh-Oberhuber 1 and 2) 85, 86 .
The presence of mild histological lesions represents a difficult to interpret "gray area". Current data suggest that patients with lymphocytic duodenosis (>25 IELs per 100 epithelial cells), may suffer from gastrointestinal and extraintestinal symptoms, such as osteopenia or anemia, as frequently as patients with villous atrophy 97, 98 . However, It should be noted that lymphocytic duodenosis, is common in the general population (prevalence of 5.4%) 99 and there are conditions other than CD in which lymphocytic duodenosis is possible. Examples of these include H.pylori infection, medications (e.g., non-steroidal anti-inflammatory drugs), small-bowell bacterial overgrowth, food protein intolerance or autoimmune disorders 91, 92 .
Furthermore, celiac serology is positive only in 10-30% of patients with lymphocytic duodenosis secondary to CD. Consequently, diagnosis of CD in these patients is not easy and requires the following conditions the mucosa seem to be specific for CD 100, 101 . However, these techniques require frozen or fresh nonfixed biopsies, and they are not straightforward for use in clinical practice.
Positive CD-Specific Serology But Absence of Enteropathy
False positive anti-TG2 results are rare but do occur and are usually low titer (typically less than twice the upper limit of normal). Repeating the test using an assay that uses human TG2 as the capture antigen may resolve the discrepancy. The duodenal biopsy should be reviewed by a pathologist familiar with CD to look for subtle abnormalities.
If these two steps do not reconcile the results, the patient can be placed on a high gluten diet and, after 6 to 12 weeks, it should be repeated the upper endoscopy with multiple additional biopsies of bulb and distal duodenum. 
Diagnosis Among Patients on a Gluten Free Diet
While standard diagnostic tests (specific serology and intestinal biopsy) have a high positive predictive value for CD, they should not be relied upon to exclude CD in patients already adhering to a GFD. The specific serologic and histologic features of CD do not normalize immediately upon the initiation of a GFD, but some patients might quickly revert to normal on a GFD. Hence, normal serologic and histologic findings on a GFD cannot be used to exclude CD definitively 14 .
HLA-DQ2/DQ8 genotyping are not influenced by diet and can be used to evaluate the likelihood of CD in patients either on a normal or on a GFD.
HLA-DQ2/DQ8 testing should be performed to try to exclude CD prior to embarking on a formal GC as a negative result will obviate the need for further workup 14 .
Gluten challenge remains the gold standard for CD diagnosis in HLA-DQ2 or -DQ8-positive patients who have normal serologic and histologic findings when tested on a GFD. It must be noted that patients who develop severe symptoms following gluten ingestion are not suitable candidates for GC.
Although gluten challenge with a diet containing at least 10 g of gluten per day for 6-8 weeks has long been the norm, there are few data to indicate the diagnostic efficacy of this approach or the optimum dose or duration of challenge 103 .
Despite the disadvantages of neither confirming nor excluding a diagnosis of CD, some patients will opt to continue on a strictly GFD without undergoing formal gluten challenge; such patients should be managed in a similar fashion to those with known CD 14 .
Differentiation of Celiac Disease from Non-celiac Gluten Sensitivity
Celiac disease should be differentiated from non-celiac gluten sensitivity in order to identify the risk for nutritional deficiency states, complications of CD, risk for CD and associated disorders in family members, and to influence the degree and duration of adherence to the GFD. Symptoms or symptoms response to a GFD alone should not be used to diagnose CD, as there is often substantial overlap in symptoms between the two conditions. A diagnosis of non-celiac gluten sensitivity should be considered only after CD has been excluded with appropriate testing 14 . Objective tests including CD-specific serology and small-intestinal histology (both obtained while the patient is consuming a gluten-rich diet) and HLA-DQ2/DQ8 testing (to rule out CD if negative) are needed to differentiate between the two disorders 104 .
Celiac Disease Diagnostic Approach in Clinical Practice
The diagnostic approach to an adult patient with suspected CD is complex,
given the diversity of possible clinical settings. Figure 3 shows CD diagnostic testing algorithm proposed by ACG clinical guideline 14 . CD-specific serology (anti-TG2, EMA or anti-DGP) should be the initial diagnostic test to be performed in patients with signs, symptoms and/or conditions associated to CD.
When IgA anti-TG2 titers are higher than 10 times the upper limit of normal, the intestinal biopsy could be excluded, since the probability of detecting villous atrophy is quite high. Hills et al. 67 showed in adults that a
IgA anti-TG2 level > 30U/ml (>10 UNL) using the Celikey test kit is absolutely predictive for CD (positive predictive value of 100%). Before taking this decision it is prudent to investigate and confirm the presence of EMA Further assessment is needed when specific serologic tests are negative but clinical suspicion of CD is high. In this situation, patients should undergo an upper endoscopy with duodenal biopsies to confirm the diagnosis of CD, (Table 8 ).
